TradingKey

關於 Replimune Group Inc 公司

Replimune Group, Inc. 是一家臨牀階段生物技術公司，致力於開發新型溶瘤免疫療法。該公司專有的 RPx 平臺基於強效的 HSV-1 骨架，旨在最大限度地提高免疫原性細胞死亡和誘導全身抗腫瘤免疫反應。RP1（vusolimogene oderparepvec）是其主要候選產品，基於專有的單純皰疹病毒株，經過工程改造，並在基因上配備了融合蛋白（GALV-GP R-）和 GM-CSF，旨在最大限度地提高腫瘤殺傷力、腫瘤細胞死亡的免疫原性和激活全身抗腫瘤免疫反應。該公司還在開發其他候選產品 RP2 和 RP3，以增強抗腫瘤免疫反應，旨在治療其他腫瘤類型，包括傳統上免疫反應較弱的腫瘤類型。 RP2 還表達抗 CTLA-4 抗體樣分子，以及 GALV-GP R 和 GM-CSF。

公司簡介

公司代碼REPL

公司名稱Replimune Group Inc

上市日期Jul 20, 2018

CEODr. Sushil Patel, Ph.D.

員工數量479

證券類型Ordinary Share

年結日Jul 20

公司地址500 Unicorn Park Dr

城市WOBURN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編01801-3377

電話17812229600

網址https://www.replimune.com/

公司代碼REPL

上市日期Jul 20, 2018

CEODr. Sushil Patel, Ph.D.

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Philip Astley-Sparke

Executive Chairman of the Board

1.32M

+5.99%

Dr. Sushil Patel, Ph.D.

Chief Executive Officer, Director

81.28K

-55.32%

Ms. Emily Luisa Hill

Chief Financial Officer

36.86K

-32.20%

Dr. Konstantinos Xynos, M.D.

Chief Medical Officer

33.93K

-17.52%

Mr. Christopher (Chris) Sarchi

Chief Commercial Officer

27.88K

-78.27%

Mr. Joseph P. (Joe) Slattery, CPA

Independent Director

6.67K

--

Mr. Christopher F. Brinzey

Investor Relations

--

Mr. Dieter Weinand

Lead Independent Director

--

Ms. Veleka Peeples-Dyer

Independent Director

--

Ms. Christy J. Oliger

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Philip Astley-Sparke

Executive Chairman of the Board

1.32M

+5.99%

Dr. Sushil Patel, Ph.D.

Chief Executive Officer, Director

81.28K

-55.32%

Ms. Emily Luisa Hill

Chief Financial Officer

36.86K

-32.20%

Dr. Konstantinos Xynos, M.D.

Chief Medical Officer

33.93K

-17.52%

Mr. Christopher (Chris) Sarchi

Chief Commercial Officer

27.88K

-78.27%

Mr. Joseph P. (Joe) Slattery, CPA

Independent Director

6.67K

--

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 7月27日週日

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

14.20%

T. Rowe Price Associates, Inc.

13.79%

BlackRock Institutional Trust Company, N.A.

6.75%

Redmile Group, LLC

6.30%

Forbion Capital Partners

5.02%

Other

53.95%

持股股東

佔比

Baker Bros. Advisors LP

14.20%

T. Rowe Price Associates, Inc.

13.79%

BlackRock Institutional Trust Company, N.A.

6.75%

Redmile Group, LLC

6.30%

Forbion Capital Partners

5.02%

Other

53.95%

股東類型

持股股東

佔比

Investment Advisor

36.07%

Hedge Fund

31.49%

Investment Advisor/Hedge Fund

26.65%

Venture Capital

9.20%

Individual Investor

3.02%

Research Firm

2.61%

Bank and Trust

0.34%

Pension Fund

0.23%

Insurance Company

0.03%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

374

87.33M

112.37%

-11.99M

2025Q1

385

87.62M

114.03%

-12.35M

2024Q4

379

83.57M

108.59%

-8.22M

2024Q3

364

75.43M

109.54%

-13.17M

2024Q2

356

76.19M

113.04%

-8.45M

2024Q1

339

72.12M

117.78%

-11.10M

2023Q4

328

71.51M

121.06%

+610.98K

2023Q3

311

68.80M

117.09%

+4.78M

2023Q2

308

66.67M

115.61%

+3.48M

2023Q1

306

60.20M

107.84%

+2.81M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

11.05M

14.33%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

10.73M

13.91%

-114.25K

-1.05%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.25M

6.81%

+493.29K

+10.36%

Mar 31, 2025

Redmile Group, LLC

4.90M

6.35%

-7.00K

-0.14%

Mar 31, 2025

Forbion Capital Partners

3.91M

5.07%

-60.97K

-1.54%

Mar 31, 2025

The Vanguard Group, Inc.

3.82M

4.96%

+232.85K

+6.49%

Mar 31, 2025

Tang Capital Management, LLC

2.90M

3.76%

+200.00K

+7.41%

Mar 31, 2025

Marshall Wace LLP

2.49M

3.23%

+1.59M

+177.59%

Mar 31, 2025

Sofinnova Investments, Inc

2.48M

3.22%

-669.58K

-21.26%

Mar 31, 2025

State Street Global Advisors (US)

2.40M

3.11%

+194.00K

+8.80%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

Tema Oncology ETF

0.53%

ALPS Medical Breakthroughs ETF

0.48%

SPDR S&P Biotech ETF

0.19%

iShares Micro-Cap ETF

0.14%

T Rowe Price Small-Mid Cap ETF

0.14%

Direxion Daily S&P Biotech Bull 3X Shares

0.11%

JPMorgan Fundamental Data Science Small Core ETF

0.1%

Optimize Strategy Index ETF

0.08%

ProShares Ultra Nasdaq Biotechnology

0.08%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.85%

Tema Oncology ETF

佔比0.53%

ALPS Medical Breakthroughs ETF

佔比0.48%

SPDR S&P Biotech ETF

佔比0.19%

iShares Micro-Cap ETF

佔比0.14%

T Rowe Price Small-Mid Cap ETF

佔比0.14%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.11%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.1%

Optimize Strategy Index ETF

佔比0.08%

ProShares Ultra Nasdaq Biotechnology

佔比0.08%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Replimune Group Inc

5.440USD

Replimune Group Inc

5.440

概覽

公司

財務